Compare FirstEnergy Corp. (FE) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Organon & Co. Common Stock — how do they compare? FirstEnergy Corp. trades at $45.73 (market cap $26.16B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: FirstEnergy Corp. is far larger — about 7.2× Organon & Co. Common Stock's market cap, and FirstEnergy Corp. pays the higher dividend (4.11%). Which is the better fit depends on your goals — on Pluang, investors hold FirstEnergy Corp. for 72 Days and Organon & Co. Common Stock for 0 Days on average.
| FE | OGN | |
|---|---|---|
Market Cap | $26.16B | $3.62B |
Volume | 4,932,658 | 2,892,999 |
Sector | Utilities | Health |
52-Week High | $51.91 | $13.81 |
52-Week Low | $43.04 | $5.70 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $55.08B | $11.04B |
Dividend Yield | 4.11% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $45.41, up 0.11% with a bullish technical signal. The stock shows mixed earnings performance with Q1 2026 beating expectations but Q4 2025 and Q2 2026 missing. Revenue grew to $15.09B in 2025 with a 6.86% net margin. Analyst consensus is Moderate Buy with a $51.00 price target, representing 12.3% upside. Recent developments include the Energize365 investment plan and consistent dividend payments.
FirstEnergy presents a stable utility investment with moderate growth potential through infrastructure investments. Key opportunities include the $36B Energize365 plan and rising data-center demand. Risks include high debt levels ($24.03B total debt), interest rate sensitivity, and regulatory challenges. The stock offers income through dividends but faces execution risks on capital projects.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
